$RGPX
REGENEREX PHARMA, INC.

2024 Q4 Form 10-Q Financial Statement

#000147237524000090 Filed on November 04, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2024 Q1
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $258.4K
YoY Change -90.73%
Operating Profit -$258.4K
YoY Change -90.73%
Interest Expense $266.2K
YoY Change 1244.16%
% of Operating Profit
Other Income/Expense, Net -$271.2K
YoY Change 1646.67%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$529.6K
YoY Change -81.1%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding 278.4M shares 278.3M shares 278.0M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q4 2024 Q3 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $294.00 $372.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses $1.541K $2.540K
Receivables
Other Receivables
Total Short-Term Assets $1.835K $2.912K
YoY Change -90.51% 156.56%
LONG-TERM ASSETS
Property, Plant & Equipment $5.232K $6.097K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $631.1K $763.8K
YoY Change -30.9% 14033.38%
TOTAL ASSETS
Total Short-Term Assets $1.835K $2.912K
Total Long-Term Assets $631.1K $763.8K
Total Assets $633.0K $766.7K
YoY Change -32.13% 11624.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $154.6K $116.8K
YoY Change 72.1% 55.38%
Accrued Expenses $126.3K $97.25K
YoY Change 53.99% -22.69%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.851M $3.843M
YoY Change 45.33% 394.78%
LONG-TERM LIABILITIES
Long-Term Debt $184.2K
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $184.2K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $4.851M $3.843M
Total Long-Term Liabilities $0.00 $184.2K
Total Liabilities $5.390M $4.829M
YoY Change 18.05% 327.5%
SHAREHOLDERS EQUITY
Retained Earnings -$6.418M -$5.616M
YoY Change 26.86% 171.03%
Common Stock $278.4K $278.2K
YoY Change 0.19% 0.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$4.757M -$4.062M
YoY Change
Total Liabilities & Shareholders Equity $633.0K $766.7K
YoY Change -32.13% 11624.73%

Cashflow Statement

Concept 2024 Q4 2024 Q3 2024 Q1
OPERATING ACTIVITIES
Net Income -$529.6K
YoY Change -81.1%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
dei Entity Address City Or Town
EntityAddressCityOrTown
Las Vegas
dei Entity Address State Or Province
EntityAddressStateOrProvince
NV
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
89108
dei City Area Code
CityAreaCode
(877)
dei Local Phone Number
LocalPhoneNumber
761-7479
CY2023Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
190000 shares
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--03-31
dei Entity Central Index Key
EntityCentralIndexKey
0001357878
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
539594 usd
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
681798 usd
CY2024Q3 us-gaap Liabilities
Liabilities
5390117 usd
CY2024Q1 us-gaap Liabilities
Liabilities
4828506 usd
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
675000000 shares
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
675000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
278435910 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
278435910 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
278225910 shares
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1275798 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-6417982 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5615850 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-4757163 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-4061826 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
632954 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
766680 usd
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
usd
RGPX Noncash Extension Fee To Greenwich Resources
NoncashExtensionFeeToGreenwichResources
usd
us-gaap Payments To Acquire Furniture And Fixtures
PaymentsToAcquireFurnitureAndFixtures
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
usd
RGPX Repayment Of Notes Payable To Shareholder
RepaymentOfNotesPayableToShareholder
usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
usd
RGPX Proceeds From Notes Payable To Shareholder
ProceedsFromNotesPayableToShareholder
usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
us-gaap Interest Paid
InterestPaid
usd
us-gaap Interest Paid
InterestPaid
usd
RGPX Operating Leases Rou Asset And Liabilities
OperatingLeasesRouAssetAndLiabilities
usd
RGPX Noncash Or Part Noncash Acquisition Of Intangible Assets Excluding Goodwill
NoncashOrPartNoncashAcquisitionOfIntangibleAssetsExcludingGoodwill
usd
RGPX Note Payable For Interest Expense
NotePayableForInterestExpense
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-53230
dei Entity Registrant Name
EntityRegistrantName
REGENEREX PHARMA, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-0479983
dei Entity Address Address Line1
EntityAddressAddressLine1
5348 Vegas Drive #177
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
278435910 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
294 usd
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
372 usd
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1541 usd
CY2024Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2540 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
1835 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
2912 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
30392 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
29272 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
208 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1328 usd
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2465 usd
CY2024Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1600 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5232 usd
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6097 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
625679 usd
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
756343 usd
CY2024Q3 us-gaap Assets
Assets
632954 usd
CY2024Q1 us-gaap Assets
Assets
766680 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
154616 usd
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
116760 usd
CY2024Q3 RGPX Related Party Advances
RelatedPartyAdvances
3690 usd
CY2024Q1 RGPX Related Party Advances
RelatedPartyAdvances
3690 usd
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
705617 usd
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
511847 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
126328 usd
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
97251 usd
CY2024Q3 us-gaap Notes Payable Current
NotesPayableCurrent
2824232 usd
CY2024Q1 us-gaap Notes Payable Current
NotesPayableCurrent
2400000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
166308 usd
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
128264 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4850523 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
3843362 usd
CY2024Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
184232 usd
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
278225910 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
278436 usd
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
278226 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1382383 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
258384 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
385923 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
512664 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
546097 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2400000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2400000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
258384 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
2785923 usd
us-gaap Operating Expenses
OperatingExpenses
512664 usd
us-gaap Operating Expenses
OperatingExpenses
2946097 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-258384 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2785923 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-512664 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2946097 usd
CY2024Q3 us-gaap Interest Expense
InterestExpense
266157 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
19801 usd
us-gaap Interest Expense
InterestExpense
288490 usd
us-gaap Interest Expense
InterestExpense
38307 usd
CY2024Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-5031 usd
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
4275 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-978 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2620 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-271188 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-15526 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-289468 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-40927 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-529572 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2801449 usd
us-gaap Net Income Loss
NetIncomeLoss
-802132 usd
us-gaap Net Income Loss
NetIncomeLoss
-2987024 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.00
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.01
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.00
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.01
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
278281562 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
277516358 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
278254052 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
277337306 shares
us-gaap Net Income Loss
NetIncomeLoss
-802132 usd
us-gaap Net Income Loss
NetIncomeLoss
-2987024 usd
us-gaap Depreciation
Depreciation
1985 usd
us-gaap Depreciation
Depreciation
1975 usd
us-gaap Share Based Compensation
ShareBasedCompensation
56795 usd
us-gaap Share Based Compensation
ShareBasedCompensation
133388 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
2400000 usd
RGPX Noncash Extension Fee To Greenwich Resources
NoncashExtensionFeeToGreenwichResources
240000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
26504 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
22880 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-978 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2620 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
999 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-13250 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
70086 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
92993 usd
RGPX Increase Decrease In Accrued Compensation
IncreaseDecreaseInAccruedCompensation
193770 usd
RGPX Increase Decrease In Accrued Compensation
IncreaseDecreaseInAccruedCompensation
96885 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
29077 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-43753 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-181938 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-293286 usd
us-gaap Payments To Acquire Furniture And Fixtures
PaymentsToAcquireFurnitureAndFixtures
6299 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6299 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
2437 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
34000 usd
RGPX Repayment Of Notes Payable To Shareholder
RepaymentOfNotesPayableToShareholder
10000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
131860 usd
RGPX Proceeds From Notes Payable To Shareholder
ProceedsFromNotesPayableToShareholder
2843 usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
50000 usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
343250 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
181860 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
304530 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-78 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4945 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
372 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1135 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
294 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6080 usd
RGPX Accrued Interest Converted Into Note Payable To Shareholder
AccruedInterestConvertedIntoNotePayableToShareholder
26622 usd
RGPX Accrued Interest Converted Into Note Payable To Shareholder
AccruedInterestConvertedIntoNotePayableToShareholder
25649 usd
RGPX Accrued Interest Converted Into Note Payable To Related Parties
AccruedInterestConvertedIntoNotePayableToRelatedParties
5616 usd
RGPX Accrued Interest Converted Into Note Payable To Related Parties
AccruedInterestConvertedIntoNotePayableToRelatedParties
52545 usd
RGPX Operating Leases Rou Asset And Liabilities
OperatingLeasesRouAssetAndLiabilities
953535 usd
RGPX Noncash Or Part Noncash Acquisition Of Intangible Assets Excluding Goodwill
NoncashOrPartNoncashAcquisitionOfIntangibleAssetsExcludingGoodwill
2400000 usd
RGPX Note Payable For Interest Expense
NotePayableForInterestExpense
240000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-1122947 usd
CY2023Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
190000 shares
CY2023Q2 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
30000 shares
CY2023Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
34554 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-185575 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-1083968 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-1083968 usd
CY2023Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
153250 shares
CY2023Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
153250 shares
CY2023Q3 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
430000 shares
CY2023Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
98834 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2801449 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-3633333 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-4061826 usd
CY2024Q2 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
30000 shares
CY2024Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
20997 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-272560 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-4313389 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-4313389 usd
CY2024Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
50000 shares
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
50000 usd
CY2024Q3 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
130000 shares
CY2024Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
35798 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-529572 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-4757163 usd
us-gaap Nature Of Operations
NatureOfOperations
<p style="margin: 0px; font-size: 10pt"><b>NOTE 1 – NATURE OF OPERATIONS</b></p> <p style="margin: 0px; font-size: 10pt"> </p> <p style="margin: 0px; font-size: 10pt">Regenerex Pharma, Inc., formerly Peptide Technologies, Inc. (the “Company” or “Regenerex”), was incorporated in the State of Nevada, United States of America, on November 18, 2005.</p> <p style="margin: 0px; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">On November 15, 2021, the Company entered into an Asset Purchase Agreement in which the Company purchased certain intellectual property in exchange for 150,000,000 shares of the Company’s common stock and up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15<sup>th</sup> of the following month, for a period of 60 months.  On August 17, 2023, the Company entered into an Agreement to Purchase Technology Platforms in which the Company purchased certain intellectual property in exchange for an interest-free two million four hundred thousand dollars ($2,400,000) note payable that was due August 17, 2024.   Since the Company has not raised a minimum of ten million dollars ($10,000,000) in sales within the twelve (12) month period, or raised a minimum of ten million dollars ($10,000,000) in investment, the seller extended the payments for a further period of twelve (12) months for a 10% payment of the outstanding balance.  An interest-free note payable was issued for $240,000 and is due August 17, 2025.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">The Company received all rights and title to proprietary wound healing technologies platforms and formulas involving the application of wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns and surgical wounds.  These unique products strategically position the Company to enter the wound treatment market in the U.S.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Risks and Uncertainties </i></p> <p style="margin: 0px; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">Our business and our forward-looking statements involve substantial known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding the impacts of COVID-19, or other future pandemics on our business, results of operations, financial position, and cash flows.</p> <p style="margin: 0px; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">The Company has a lack of revenue history and has had a limited history of operations.  No revenue has historically been derived from the assets purchased.  Regenerex can give no assurance of success or profitability to the Company’s investors.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt">The wound care healing space is well suited for Home Care service providers that are funded by the US Government. Strategic planning and development will be performed internally by the Company.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p>
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2005-11-18
CY2021Q4 us-gaap Asset Acquisition Contingent Consideration Liability
AssetAcquisitionContingentConsiderationLiability
10000000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-4757163 usd
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2910250 shares
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2306250 shares
CY2024Q3 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P3Y
CY2024Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
405 usd
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
723 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1120 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1437 usd
us-gaap Property Plant And Equipment Preproduction Design And Development Costs
PropertyPlantAndEquipmentPreproductionDesignAndDevelopmentCosts
<p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Furniture and Computer Equipment</i></p> <p style="margin: 0px; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">Furniture and computer equipment are stated at cost, less accumulated depreciation.  Depreciation is computed using the straight-line method over the estimated useful life of three (3) to five (5) years.  Depreciation expense for the three and six months ended September 30, 2024 and 2023 was $430 and $422 and $865 and $538, respectively.  Significant betterments are capitalized while purchases under $500 are expensed as incurred.</p> <p style="margin: 0px; font-size: 10pt"> </p>
CY2024Q3 us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
430 usd
CY2023Q3 us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
422 usd
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
865 usd
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
538 usd
CY2024Q3 us-gaap Lessee Finance Lease Discount Rate
LesseeFinanceLeaseDiscountRate
0.10 pure
us-gaap Related Party Transaction Rate
RelatedPartyTransactionRate
0.10 pure
CY2024Q3 RGPX Related Party Advances
RelatedPartyAdvances
3690 usd
CY2024Q1 RGPX Related Party Advances
RelatedPartyAdvances
3690 usd
CY2024Q3 RGPX Notes Payable Related Parties
NotesPayableRelatedParties
247976 usd
CY2024Q1 RGPX Notes Payable To Related Parties Net Of Current Portion
NotesPayableToRelatedPartiesNetOfCurrentPortion
110500 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
9101 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
1630 usd
CY2021Q4 us-gaap Business Combination Contingent Consideration Arrangements Description
BusinessCombinationContingentConsiderationArrangementsDescription
up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15th of the following month, for a period of 60 months
CY2021Q4 us-gaap Asset Acquisition Contingent Consideration Liability
AssetAcquisitionContingentConsiderationLiability
10000000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
1650 usd
us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
On June 10, 2023, the Company entered into a plant facility lease agreement with a related party commencing June 9, 2023 which expires on June 30, 2028.  Under this agreement, the monthly rental payments are $18,000 throughout the term of the lease excepting the month of June 2023 the rent is $7,920, To commence with production, the plant needs to prepare for FDA inspection which will include inspection of the facility, equipment, and the Company’s procedures.  We expect to launch production during the Company’s third or fourth quarter and will notify the FDA to come into the plant for the inspection at that time.  The Company is able to start production while the plant waits for the FDA Inspection.  Until the certification is complete, the monthly rent is reduced by forty (40%) percent to $10,800. Under this agreement, the Company is also leasing the equipment in the plant facility through five (5) annual rent payments of $10,000, which are due on the 15thday of  each June from June 2023 to June 2027.
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
675000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2910250 shares

Files In Submission

Name View Source Status
0001472375-24-000090-index-headers.html Edgar Link pending
0001472375-24-000090-index.html Edgar Link pending
0001472375-24-000090.txt Edgar Link pending
0001472375-24-000090-xbrl.zip Edgar Link pending
exhibit31-1.htm Edgar Link pending
exhibit31-2.htm Edgar Link pending
exhibit32-1.htm Edgar Link pending
exhibit32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
ixform10q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ixform10q_htm.xml Edgar Link completed
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
regenerexlogo.gif Edgar Link pending
report.css Edgar Link pending
rgpx-20240930.xsd Edgar Link pending
Show.js Edgar Link pending
rgpx-20240930_cal.xml Edgar Link unprocessable
rgpx-20240930_def.xml Edgar Link unprocessable
rgpx-20240930_lab.xml Edgar Link unprocessable
rgpx-20240930_pre.xml Edgar Link unprocessable